Boc-N-Me-Ala-Tle-Pro-OH | 762274-48-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-N-Me-Ala-Tle-Pro-OH
• 英文别名: (2S)-1-[(2S)-2-[(2S)-2-[[(tert-butoxy)carbonyl](methyl)amino]propanamido]-3,3-dimethylbutanoyl]pyrrolidine-2-carboxylic acid；((S)-2-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)-3,3-dimethylbutanoyl)-L-proline；1-{2-[2-(tert-butoxycarbonyl-methyl-amino)-propionylamino]-3,3-dimethyl-butyryl}-pyrrolidine-2-carboxylic acid；(S)-1-((S)-2-((S)-2-(tert-butoxycarbonyl(methyl)amino)propanamido)-3,3-dimethylbutanoyl)pyrrolidine-2-carboxylic acid；Boc-N(Me)Ala-Gly(tBu)-Pro-OH；(2S)-1-[(2S)-3,3-dimethyl-2-[[(2S)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoyl]amino]butanoyl]pyrrolidine-2-carboxylic acid
• CAS: 762274-48-6
• 化学式: C₂₀H₃₅N₃O₆
• 分子量: 413.514
• InChiKey: VUJYXTPIFCPRBX-MELADBBJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Boc-N-Me-Ala-Tle-Pro-OH 在 N-羟基-7-氮杂苯并三氮唑 、 PS-carbodiimide resin 、 三异丙基硅烷 、 N,N-二甲基乙酰胺 、 三氟乙酸 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 19.0h， 生成 (S)-1-[(S)-3,3-dimethyl-2-((S)-2-methylamino-propionylamino)-butyryl]-pyrrolidine-2-carboxylic acid phenethyl-amide
  参考文献：
  名称：

  Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer

  摘要：

  Inhibitor of apoptosis (IAP) proteins are overexpressed in many cancers and have been implicated in tumor growth, pathogenesis, and resistance to chemo- or radiotherapy. On the basis of the NMR structure of a SMAC peptide complexed with the BIR3 domain of X-linked IAP (XIAP), a novel series of XIAP antagonists was discovered. The most potent compounds in this series bind to the baculovirus IAP repeat 3 (BIR3) domain of XIAP with single-digit nanomolar affinity and promote cell death in several human cancer cell lines. In a MDA-MB-231 breast cancer mouse xenograft model, these XIAP antagonists inhibited the growth of tumors. Close structural analogues that showed only weak binding to the XIAP-BIR3 domain were inactive in the cellular assays and showed only marginal in vivo activity. Our results are consistent with a mechanism in which ligands for the BIR3 domain of XIAP induce apoptosis by freeing up caspases. The present study validates the BIR3 domain of XIAP as a target and supports the use of small molecule XIAP antagonists as a potential therapy for cancers that overexpress XIAP.

  DOI：

  10.1021/jm040037k
• 作为产物：
  描述：

  N-Boc-L-叔亮氨酸 在 palladium on activated charcoal 盐酸 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.16h， 生成 Boc-N-Me-Ala-Tle-Pro-OH
  参考文献：
  名称：

  Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer

  摘要：

  Inhibitor of apoptosis (IAP) proteins are overexpressed in many cancers and have been implicated in tumor growth, pathogenesis, and resistance to chemo- or radiotherapy. On the basis of the NMR structure of a SMAC peptide complexed with the BIR3 domain of X-linked IAP (XIAP), a novel series of XIAP antagonists was discovered. The most potent compounds in this series bind to the baculovirus IAP repeat 3 (BIR3) domain of XIAP with single-digit nanomolar affinity and promote cell death in several human cancer cell lines. In a MDA-MB-231 breast cancer mouse xenograft model, these XIAP antagonists inhibited the growth of tumors. Close structural analogues that showed only weak binding to the XIAP-BIR3 domain were inactive in the cellular assays and showed only marginal in vivo activity. Our results are consistent with a mechanism in which ligands for the BIR3 domain of XIAP induce apoptosis by freeing up caspases. The present study validates the BIR3 domain of XIAP as a target and supports the use of small molecule XIAP antagonists as a potential therapy for cancers that overexpress XIAP.

  DOI：

  10.1021/jm040037k

文献信息

• [EN] ALANINE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE<br/>[FR] MODULATEURS DE PROTÉOLYSE À BASE D'ALANINE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS INC

  公开号：WO2017011590A1

  公开（公告）日：2017-01-19

  The description relates to inhibitors of Apoptosis Proteins (TAPs) binding compounds, including Afunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the IAP E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

  描述涉及抑制凋亡蛋白（TAPs）结合化合物，包括包含相同的A功能化合物，这些化合物作为靶向泛素化的调节剂发挥作用，特别是根据本发明的双功能化合物抑制各种多肽和其他蛋白质的化合物。具体而言，描述提供了一端含有结合到IAP E3泛素连接酶的配体，另一端含有结合到靶蛋白的基团的化合物，使得靶蛋白靠近泛素连接酶以促使该蛋白的降解（和抑制）。可以合成化合物，表现出与几乎任何类型的靶向多肽的降解/抑制一致的广泛药理活性。
• Design, synthesis and biological evaluation of new bivalent quinazoline analogues as IAP antagonists
  作者：Inhwan Bae、Daejin Kim、Jaeyul Choi、Jisook Kim、Minjeong Kim、Bokyung Park、Young Hoon Kim、Young Gil Ahn、Ha Hyung Kim、Dae Kyong Kim

  DOI：10.1016/j.bmcl.2020.127676

  日期：2021.2

  We recently reported the biological evaluations of monovalent IAP antagonist 7 with good potency (MDA-MB-231, IC50 = 19 nM). In an effort to increase cellular activity and improve favorable drug-like properties, we newly designed and synthesized bivalent analogues based on quinazoline structure of 7. Optimization of cellular potency and CYP inhibition led to the identification of 27, which showed dramatic

  我们最近报道了具有良好效力的单价IAP拮抗剂7的生物学评估（MDA-MB-231，IC 50  = 19 nM）。为了提高细胞活性并改善类似药物的有利性质，我们基于7的喹唑啉结构新设计并合成了二价类似物。细胞效价和CYP抑制的优化导致27的鉴定，显示出超过100倍的急剧增加（IC 50  = 0.14 nM），并在MDA-MB-231异种移植模型中引起实质性的肿瘤消退。这些结果强烈支持27作为一种有前途的二价拮抗剂，用于开发有效的抗肿瘤方法。
• SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS
  申请人：HANSON Gunnar

  公开号：US20090104151A1

  公开（公告）日：2009-04-23

  The invention provides small molecule mimics of the Smac peptide that are dimer-like or trimer-like compounds having two or three amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.

  本发明提供了Smac肽的小分子模拟物，这些模拟物是二聚体或三聚体化合物，具有由连接剂连接的两个或三个含酰胺的结构域。这些化合物对促进细胞凋亡很有用。本发明还包括包含这些化合物的药物组成物和使用它们治疗包括癌症和自身免疫性疾病在内的疾病的方法。
• Tetrapeptide analogs
  申请人：Chao Bin

  公开号：US20100190688A1

  公开（公告）日：2010-07-29

  Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer are provided.

  提供了用于治疗过度增殖性疾病，如癌症的化合物、组合物和方法。
• QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS
  申请人：Bae In Hwan

  公开号：US20130165386A1

  公开（公告）日：2013-06-27

  Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

  提供的是一种药物组合物，包含一种式子为(I)的喹啉或喹嗪衍生物作为活性成分，以及其药学上可接受的盐、异构体、水合物和溶剂化物。该组合物对于预防和治疗由凋亡抑制蛋白(IAPs)过度表达引起的癌症、炎症、自身免疫性疾病或神经退行性疾病具有有效性。